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Abstract
Microneme 3 (MIC3) protein tachyzoites Toxoplasma gondii is one of protein which plays an important role
during cell host invasion. Gene encoding MIC3 protein has been studied and it was suggested a potent vaccine
candidate against Toxoplasma gondii infection. The aim of this research is to clone and sequence the gene encoding
MIC3 protein of tachyzoites Toxoplasma gondii local isolate by amplification using polymerase chain reaction with
specific primers. The amplified DNA fragment was cloned into pGEM-T and transformed into E. coli XL-1 Blue by
heat shock method. Recombinant plasmids were isolated using alkali lysis method and analyzed by digestion
using restriction endonuclease enzymes PstI, HindIII, NcoI and EcoRV. The recombinant plasmids then sequenced
to find out the nucleotide sequence of insert gene by ABIPRISM 377 DNA Sequencer. The DNA sequence then
were analyzed by computer software for alignment. The result showed that transformation in E. coli XL-1 Blue by
pGEM-T produced one clone that was encoding MIC3 protein. Analysis of 489 bp from 5’ and 447 from 3’ of gene
sequence showed 97-98% homology with gene encoding for MIC3 protein of RH isolate.
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Introduction
Infection by Toxoplasma gondii are widely
prevalent in animals and human all over the
world. Toxoplasma gondii  is an obligate
intracellular  protozoan parasite that infects
all warm-blooded animals, including
human, belonging to the phylum
Apicomplexa. Other members of this
phylum include the human pathogens
Plasmodium and Cryptosporodium as well as
the animals pathogens Eimeria and
Sarcocystis. Cat and members of the cat
family (Felidae) are the definitive hosts of
Toxoplasma gondii,with many mammals and
birds serving as intermediate hosts. Animals
and human acquire Toxoplasma by ingesting
any of three infectious stages of the parasite:
The rapid multiplying forms called
tachyzoites, silent forms that occupy cysts
in infected tissue called bradyzoites and
oocysts shed in feces of infected cats. For
human, infection could be ingestion of tissue
cysts in under cooked meat and ingestion of
water or food contaminated with oocysts.
Widespread natural infection is possible
because cats may excrete millions of oocysts
after ingesting only a few tissue cysts from
the infected animas.   Toxoplasma gondii
infects about 10%- 25% of world’s
population, more than 500 million people
infected by Toxoplasma gondii. Toxoplasma
gondii often cause subclinical infection or
asymptomatic, but primary infection during
pregnancy can lead to miscarriage and
congenital defects (Gandahusada, 1998;
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Vercammen et al., 2000). In
immunosuppressed patients, this relative
benign infection may reactivate and exhibit
severe symptom including encephalitis,
myocarditis, hepatitis and multisystem
organ failure (Scorza et al., 2003). Serological
tests can be used to diagnose during acute
toxoplasmosis but not always give accurate
results (Gandahusada, 1998). Pyrimetamine
and sulfonamide combination so far can use
to treat toxoplasmosis case. These
medications only affect to the tachyzoite but
not the cyst form, so it can overcome acute
infection but not chronic infection which can
reactivate again (Gandahusada, 1998).
Vaccine for toxoplasmosis is important to
prevent fetal infections, reactivation in
imunocompromised patients, and control
tachyzoite multiplication which associated
with the acute primary infection (Denkers et
al., 1998; Sibley et al., 1996). Thus, biological
molecular development diagnostic kit and
vaccine is an important thing to do in an
attempt to overcome these problems.
Attenuated Toxoplasma gondii tachyzoite
vaccines have been successfully employed
for animal use, but vaccination with live
organisms cannot be safely performed in
humans. The approach to a human
toxoplasmosis vaccine must be based on the
use of recombinant antigens or synthetic
peptides that, ideally should protect the host
from the all life cycle stages of the parasite
Toxoplasma gondii (Prigione et al., 2000).  In
the investigation of parasite antigens
involved in protective immunity, most of the
work had been focused on surface antigen
(SAGs), specifically which expressed at the
tachyzoite stage with a particular interest in
SAG1 (Prigione et al., 2000). Reports on
experimental DNA vaccination in mice have
been accumulating, and the antigens that
have been tested now include membrane-
associated surface antigen (SAG1), excreted-
secreted dense granule proteins; GRA1,
GRA4, GRA7 which expressed in both
tachyzoites and bradyzoites stages, as well
as rhoptry proteins; ROP1 and ROP2 (Scorza
et al., 2003; Prigione et al., 2000). The
micronemal protein MIC3 looks particularly
promising because it is a potent adhesion of
Toxoplasma gondii, that is expressed in all
three infectious stages of Toxoplasma gondii
(tachyzoites, bradyzoites, and sporozoites)
and that elicits early and powerful immune
responses in mice (Ismael et al., 2003).
A key step in Toxoplasma gondii infection
is host cell invasion. Invasion is concomitant
with the sequential discharge of proteins
from the two secretory organelles of the
parasite: first micronemes and then rhoptries
(Coppens and Joiner, 2001). MIC3 protein is
one of protein which  is secreted by
microneme organel during invasion by
exocytosis. MIC3 is a soluble dimeric 90 kDa
protein, synthesized as 40 kDa precursors
that are proteolytically processed to 38 kDa
final product. It has a strong affinity to host
cell surface and the ability to bind cell surface
is played out by chitin binding-like (CBL)
domain. This domain is responsible for the
adhesion and that N-terminal pro-peptide
cleavage and C-terminal dimer formation are
needed to allow the expression of this
binding property (Cerede et al., 2002; 2005;
Black et al., 2000). Gene encoding MIC3
protein has 2247 bp in length and contain no
intron (Garcia-Reguet et al., 2000).
In this study, we tried to clone gene
encoding MIC3 protein tachyzoite
Toxoplasma gondii from local isolate. Isolation
of tachyzoite DNA was done after in vivo
cultivation in Balb/C mice and then
amplified using specific primers. The
amplified DNA fragment then was ligated
into  pGEM-T  vector and transformed into
Escherichia coli, so we had only clones that
carried out gene encoding MIC3 protein of
local isolate, hopefully. Recombinant
plasmids then were sequenced and
identified its homolog with gene encoding
MIC3 of RH isolate.
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Materials and Methods
Isolation of tachyzoite DNA
After parasite in vivo cultivation in
Balb/C mice and obtained 6x108 tachyzoite/
ml, intraperitoneal fluid was centrifuged and
the pellet was washed three times using PBS
then resuspended with NTE solution into the
resuspended pellet. Added with 100 μg/ml
proteinase-K and 0.5% SDS, afterward
overnight incubated in waterbath 37oC. This
reaction then was added with an equal
volume of phenol, mixed by shaking 60 rpm
for 20 min, centrifuged at 3,000 rpm for 15
min. The aqueous phase was added with an
equal volume of CIAA and centrifuged at
3,000 rpm for 10 min. This step was replated
until there was no interphase. Finally, DNA
was precipitated with 0.1 volume  3 M Na-
acetate and 2x volume ice-cold ethanol
absolute. Incubated for 15 min in -20oC,
centrifuged at maximum speed for 5 min.
Rinsed the pellet with 70% ethanol and
dissolved in TE buffer.
Amplification of target DNA
Specific primers for gene encoding MIC3
protein, M3F1 and M3R1 were diluted into
10 pmol/μl (M3F1: 5’ GTGTAAGCTTC
TTGTCCAACACTGGGTA 3’ and M3R15’
CACGGATATCTGCGAATGGGCG 3’).
Amplification was done using puRe Taq RTG-
PCR . The amplification mixture then
amplified using thermocycler (Gene Cycler,
Biorad) with program: (1) initial
denaturation at 94oC for 5 min, (2)
denaturation at 94oC for 1 min, (3) annealing
at 60oC for 1 min, (4) extension at 72oC for 1
min, (5) repeat the cycle for 35 times, and (7)
final extention at 72oC for 5 min.
Amplification was done with positive
control (RH isolate) and negative control.
Cloning and transformation
The amplified of DNA fragment was
ligated into pGEM-T vector (Promega)
according to recommended procedure.
Transformation into E. coli XL-1 Blue was
done using heat shock method at 42oC  for
90 s. Transformed E. coli then was plated on
LB agar containing ampicillin by adding,
IPTG, and X-gal. Plasmid from transformed
E. coli then was isolated by alkali method and
analyzed by digestion using endonuclease
restriction enzymes (PstI for plasmid from
blue colonies, HindIII  for plasmid from
white colonies and double digest using
EcoRV and NcoI to show the existence of the
insert).
Sequencing of recombinant plasmids
The recombinant plasmid was
sequenced using Big Dye Terminator
ABIPRISM 377 DNA Sequencer (Eijkman,
Jakarta). Sequence results were aligned using
BLAST software program which was
accessed through NCBI at http://
www.ncbi.nlm.nih.gov.
Results and Discussion
Amplification of target DNA
The entire gene encoding MIC3 is 2247
bp in length, according to gene bank (NCBI)
accession no. AJ132530. M3F1 primer
annealed from position 666 to 692 and M3R1
from 1812 to 1833; both of them were
designed to amplify gene target for 1170 bp
(position 666 to 1833), including signal
sequence (position 696 to 773) and mature
peptide (position 894 to 1772).  The sequence
of M3F1 was modified to generate HindIII
restriction site and M3R1 for EcoRV
restriction site (Figure 1).
These restriction sites later are used to
digest recombinant plasmids. The result of
DNA amplification using specific primers
can be seen at Figure 2, showed that was one
dominant band at approximately 1.2 kb at
positive control (RH isolate) and sample
(local isolate), either and there was no bands
at negative control. But there was one thin
band at 300 bp and seemed to primer dimer.
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Figure 2. Amplification of DNA using M3F1 and
M3R1 primers on  1% agarose gel. (M) marker, (1)
positive control (RH isolate), (2) sample (local isolate),
(3) negative control.
Cloning and transformation
We obtained 8 colonies on 1 plate LB agar.
They consist of 2 blue colonies and 6 white
colonies (data not shown). The plasmids
from transformed E. coli then were isolated
and digested with PstI (for plasmids from
blue colonies) and HindIII (for plasmids from
white colonies). Restriction site for PstI was
available at polycloning sites of pGEM-T
vector and site for HindIII was appropriated
from construct of M3F1 primer; pGEM-T did
not have this site (Circular map of pGEM®-T
vector (Technical Manual No. 042, Promega).
Digested plasmids from blue colonies were
3 kb in length (suitable to pGEM-T) and only
1 plasmid from white colonies had 4.2 kb size
as we desire (data not shown). This 4.2 kb
plasmid then named with pWTA-M3.
Digestion using HindIII and PstI was
performed to show the existence of  1.2 kb
insert but we could not get the result.
pWTA-M3 was linearized with HindIII. It
was 4.2 kb but after digested with PstI
became 3 kb and there were bands at
approximately 300-400 bp. Perhaps, it caused
by too many restriction sites for PstI  in insert
gene, thus the insert was digested into many
smaller fragments. In an attempt to
overcome this problem, we did double digest
using NcoI and EcoRV. We had 4.2 kb
plasmid after linearized with HindIII and
insert at 1 kb after double digested (Figure
4). This smaller insert (must be 1.2 kb) may
due to there was another site for NcoI in
insert gene.
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MIC3 from pBluescript II SK-MIC3 using
same primers and obtained amplicon at 1155
bp.
Figure 1. Construct of M3F1 and M3R1 primers.
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Figure  4.  Plasmid digestion using endonuclease
restriction enzymes on 1% agarose gel. (M) marker;
Plasmid from blue colony (1) whole plasmid, (2)
digested with PstI; pWTA-M3 (3) whole plasmid, (4)
digested with HindIII, (5) digested with NcoI and
EcoRV.
Sequencing of recombinant plasmids
Sequencing of pWTA-M3 was done with
pUC/M13 forward sequencing primer and  pUC/
M13 reverse sequencing primer (available at
pGEM-T vector construct). We had 489 bp
from 5’ and 447 bp from 3’; so there were
234 bp from 1170 of insert gene that could
not know its nucleotide sequence.
The analysis of the DNA sequence
obtained from the BLAST program revealed
a significant degree with gene encoding
MIC3 Toxoplasma gondii RH isolate. Sequence
alignment of pWTA-M3 which sequenced
using pUC/M13 forward showed 97%
homolog from base 676 until 1164, the
differences were lied on position 1074, 1075,
1129, and 1160. Alignment of pWTA-M3
sequence which sequenced using pUC/M13
reverse showed 98% homolog from base 1387-
1833, the differences were lied on base 1827
and 1825. The difference bases at 1074 and
1075 lead to alter amino acid; aspartic acid
(GAT) to glycine (GGA), difference at 1129
did not change the amino acid (CTG to CTT:
leusin), and difference at 1160 changed
aspartic acid (GAC) to glutamic acid (GAA).
Un homolog sequence at base 1825 and 1827
were not in coding sequence of gene encoding
MIC3 so did not affect the amino acid
synthesis. These changes may have no effect
to the general structure and functional of the
protein because aspartatic acid and glutamic
acid have similar property (polar/
hydrophilic) and similar size, and so do
glycine, have polar/hydrophilic property; it
just has a smaller size cause its side chain
only hydrogen (Berg et al., 2002).
Analyze of insert gene in pWTA-M3
using ChromasPro showed that it had many
restriction sites for endonuclease restriction
enzymes include PstI dan NcoI; it could
explain the problems when recombinant
plasmids analysis. The insert gene had 2 sites
for PstI (CTGCAG) at position 1016-1021 and
1424-1429 thus recombinant plasmids were
digested into 4 fragments; 1 fragment with 3
kb and 3 fragments with size at
approximately 400 bp. Double digested
using NcoI and EcoRV showed a smaller
insert because that was 1 site for NcoI
(CCATGG) at position 1646-1651 so the
plasmids were showed into 3 fragments with
3 kb and 1 kb fragment at approximately 200
kb.
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